Alumis, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Dr. Reddy’s Acquires Rights From

The proposed all-stock merger of troubled Acelyrin with Alumis, first announced on 6 February, will go forward, Acelyrin said 4 March, stating it will decline an unsolicited acquisition offer from Tan

Alumis stands to bulk up its financial position as well as its portfolio of drugs to treat immune-mediated diseases through its merger with Acelyrin. But while analysts saw the deal as a positive from

There are a few candidates with the potential to join Bristol Myers Squibb Company ’s Sotyktu in the TYK2 inhibitor space but Ventyx Biosciences, Inc. 's VTX958 is no longer one of them. The San Die